

Validation data for Jurkat-Lucia™ hCD27 Cells

<https://www.invivogen.com/jurkat-lucia-cd27>

For research use only

Version 24D29-NJ

Jurkat-Lucia™ hCD27 cells were designed for the screening of novel agonists of the immune checkpoint CD27. They stably express human CD27 at the plasma membrane, as well as an NF- κ B-inducible Lucia luciferase reporter gene. The surface expression of human CD27 in these cells compared to their parental cell line has been validated using flow cytometry (Figure 1). In the presence of a potent CD27 agonist, such as Fc-hCD70, CD27 triggering leads to NF- κ B activation and Lucia production (Figure 2).

CD27 expression on Jurkat-Lucia™ hCD27 cells




Figure 1: Validation of human CD27 surface expression by Jurkat-Lucia™ hCD27 cells. Jurkat (blue) and Jurkat-Lucia™ hCD27 (red) cells were incubated with a PE-conjugated Anti-hCD27 mAb for 30 minutes. The binding affinity was measured using flow cytometry. Unstained cells are shown in grey.

Activation of Jurkat-Lucia™ hCD27 cells using a CD27 agonist




Figure 2: Activation of Jurkat-Lucia™ hCD27 cells. Jurkat-Lucia™ hCD27 cells were incubated with increasing concentrations of recombinant human Fc-CD70 fusion protein for 24 hours. The NF- κ B activation in Jurkat-Lucia™ hCD27 cells was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™ 4. Fold responses are shown as mean \pm SEM.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3622-3480
E-mail: info@invivogen.com



Any questions about our cell lines?
Visit our FAQ page.

 **InvivoGen**
www.invivogen.com